MannKind Announces Dual Listing on the Tel Aviv Stock Exchange

VALENCIA, Calif., Oct. 23, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of MannKind's common shares beginning on October 28, 2015 under the ticker symbol MNKD. Based on the current market capitalization, MannKind's shares are anticipated to be included in five TASE equity indexes: TASE's TA-75, TA-100, TA-BlueTech, TA-Tech-Elite and TA-Biomed.

"The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving our accessibility to Israeli investors," said Hakan Edstrom, President and CEO of MannKind. "This listing is also an extension of the long-standing relationship between our Executive Chairman, Alfred Mann, and the Israeli biotechnology industry, including the Alfred Mann Institute at the Technion (Israel Institute of Technology)."

TASE CEO, Yossi Beinart said, "We welcome MannKind to the TASE Dual Listing, and believe that this is a recognition of the Biomed sector's special position at the Tel Aviv Stock Exchange. MannKind has long and strong relations with the Israeli Biomed Sector, via the founder and executive chairman Mr. Alfred E. Mann, one of pioneers of the Biomed sector in the U.S., who has supported developing and commercializing Israeli technologies for many years. We are proud that a company with a market value of more than a billion US dollars chose to join 50 dually-listed companies, as well as the TASE leading indices. Joining TASE entitles MannKind to significant benefits, including added exposure among Israeli investors, extension of the trading duration, investment by Exchange Traded Product vendors and easy access to institutional and retail investors."

Trading Regulations

MannKind's shares will continue to be listed on the Nasdaq Global Market, subject to the rules and regulations of the Nasdaq Global Market applicable to listed companies. Under Israel's Dual Listing Law, U.S.-listed companies may also list on the TASE without any additional regulatory requirements. Investors should note that the trading on the TASE occurs Sunday from 8:30 am to 4:30 pm Israel time and Monday through Thursday from 8:30 am to 5:30 pm Israel time, except on TASE trading holidays, and trading on the Nasdaq Global Market occurs Monday through Friday, 9:30 am to 4:00 pm Eastern Time, except on Nasdaq holidays. The TASE Clearing House is electronically linked to the Depository Trust Company, a subsidiary of the Depository Trust & Clearing Corporation, to automate the cross-border settlement of shares listed on both the TASE and a U.S. Exchange.

About MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the TASE equity indexes in which MannKind's shares are expected to be included. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve risks and uncertainties and are based upon the MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market factors, MannKind's dependency on Sanofi for commercialization of Afrezza, MannKind's need and ability to raise additional capital and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2014 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

CONTACT: Company Contact: Matthew J. Pfeffer Chief Financial Officer 661-775-5300

Source:MannKind Corporation